Conjugated multi-strain vaccine for meningitis

Menveo is the first conjugated multi-strain meningitis vaccine to be launched in the UK.

 It is licensed for active immunisation against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W135 and Y. The carrier protein used in Menveo, CRM197, is a naturally occurring nontoxic mutant of diphtheria toxin.

A pivotal randomised phase III trial conducted in the US compared Menveo to the US-licensed conjugated quadrivalent vaccine Menactra in 3539 healthy individuals aged 11–55 years.

Separate analyses showed Menveo to be superior to Menactra in adults (19–55 years of age) and adolescents (11–18 years of age) in terms of seroresponse rates (serogroup-specific serum bactericidal activity) 28 days after vaccination. Indeed, seroresponse rates were generally higher with Menveo than with Menactra.

Quadrivalent meningococcal vaccination should be considered in high-risk individuals travelling to the ‘meningitis belt' in sub-Saharan Africa and is compulsory for pilgrims and seasonal workers going to Mecca on the Hajj/Umra pilgrimage.

View Menveo drug record

Further information: Novartis Vaccines

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in